9 Most Profitable Biotech Stocks to Buy

3. Argenx SE (NASDAQ:ARGX)

TTM Net Income: $1.28 billion

Number of Hedge Fund Holders: 53

Argenx SE (NASDAQ:ARGX) is one of the most profitable biotech stocks to buy. Citi analyst Samantha Semenkow maintained a Buy rating on Argenx SE (NASDAQ:ARGX) on October 23 and set a price target of $1,041. Argenx SE (NASDAQ:ARGX) also received a rating update from Bank of America Securities analyst Tazeen Ahmad, who reiterated a Buy rating on the stock and lifted the price target to $942 from $887.

Ahmad based the positive rating on the company’s strong performance and the growth potential of its Vyvgart medication. The analyst stated that Argenx SE (NASDAQ:ARGX) reported impressive Q2 revenues for Vyvgart, exceeding expectations with a 20% quarter-over-quarter growth.

The Q3 revenue is expected to surpass $1 billion, supported by the drug’s expansion into new geographical regions and the approval of a prefilled syringe, which is anticipated to boost its usage and accessibility.

Argenx SE (NASDAQ:ARGX) is a biotech company that develops treatments for severe autoimmune diseases. The company operates through four segments: the United States, Japan, EMEA, and China.